Metagenomi MGX
Metagenomi Q3 FY24: revenue $11.5M; diluted EPS −$0.51
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-126273
- Document
- 10-Q
Key figures from this report
These are the numbers Metagenomi reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$11.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$18.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.51No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$25.1MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$26.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Fitlife Brands FTLF public float $51M, Jun 30, 2025
- Immucell ICCC public float $51M, Jun 30, 2025
- Cue Biopharma CUE public float $52M, Jun 30, 2025
- Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
- Precision Biosciences DTIL public float $47M, Jun 30, 2025
